RSS

Genomas Celebrates 5th Anniversary at Hartford Hospital

HARTFORD, CT – Genomas celebrates its 5th anniversary as the anchor of the Hartford Hospital
Genetics Research Center today with a ceremony and open house at the company’s laboratories.
Gualberto Ruaño, M.D., Ph.D., President of Genomas and Director of Genetics Research at Hartford
Hospital stated: “Personalized healthcare is often referred to as the ‘future of medicine’. In 5 years,
Hartford Hospital and Genomas together have advanced this field to the present for our patients, by
being at the vanguard of the practice of DNA-Guided Medicine. Foremost in my mind is a deep
appreciation to the patients we have served and to the physicians who referred them to us for
improving the safety and efficacy of their drug treatments. At a personal level, I am very honored by
the trust of our collaborators, advisers and investors on the formidable capabilities of the entire
Genomas team and by their sharing our vision of personalized medicine in clinical practice.”
With the motto “Bringing DNA-Guided Medicine to Healthcare Today”, the company will showcase its
various accomplishments to the greater biomedical and business community, including the following:
Translational Medicine Anchored in Hospital Partnerships
 Hartford Hospital (cardiovascular), Institute of Living (psychiatry), Hospital of Central Connecticut
(diabetes) and University of Puerto Rico Medical Sciences (Hispanic healthcare)
 Network of clinical resources, research collaborators, IRB-approved protocols
 Numerous medical education workshops and internships
Nationally recognized clinical practice in pharmacogenetics
 500 patients referred by physicians, 1,500 pharmacogenetic assays performed
 CLIA Certified, State-Licensed Molecular Diagnostics Laboratory of Personalized Health since 2005
 CT-wide distribution of clinical services via Clinical Laboratory Partners with payer reimbursement
Validated Science and Proven Technology Platform
 $4.3M Research grants from NIH SBIR programs and product development contracts
 30 Scientific publications and 5 national symposia
 PhysioGenomics Technology for genomic learning from patient care and the observed variability in
clinical response to treatments
 5,000 Patient clinical database and repository
PhyzioType System™ Product Development Addressing Major Clinical Needs
 Novel diagnostic configuration of PhyzioType Systems combines multi-gene DNA marker
ensembles, clinically validated algorithms to predict response, physician interface
 PIMS PhyzioType™ System for DNA-guided management of Psychotropic-Induced Metabolic
Symptoms to be launched Q4 2009
 SINM PhyzioType™ System for DNA-guided management of Statin-Induced Neuro-Myopathy to be
launched Q2 2010
 GLIM PhyzioType™ System for DNA-guided management of Glucose and Insulin Modulators in
development for diabetes medications
Strong Intellectual Property Estate
 2 Patent applications on PhysioGenomics Technology
 6 Patent applications on PhyzioType Systems for DNA-Guided Medicine
 2 registered trademarks
Seed Round Financing Completed
 $5.3M Financing in 3 Series
“In my 6 years at Hartford Hospital I have learned that the Institution thrives on providing the best
patient care while advancing clinical practice. Personalized medicine is part of a long series of
accomplishments first implemented into clinical practice at Hartford Hospital. Our PhyzioType
Systems will follow in that tradition, as patients at this Institution will be the first in the nation to benefit
from this innovative technology in DNA-Guided Medicine. Genomas is deeply indebted to the
Hospital, for pioneering a business model in translational medicine, incubating the company and
becoming its founding partner in 2004,” said Dr. Ruaño.
Elliot Joseph, President and CEO, Hartford Hospital and Hartford Healthcare, commented: “This
anniversary of Genomas is a testament to the company’s contributions not only to the development of
new biomedical technologies but also to the enhancement of patient care. In its 5 years at Hartford
Hospital, Genomas has been instrumental in advancing our institution to become one of the key
national centers of excellence in the clinical practice of personalized medicine.”

HARTFORD, CT – Genomas celebrates its 5th anniversary as the anchor of the Hartford Hospital

Genetics Research Center today with a ceremony and open house at the company’s laboratories.

Gualberto Ruaño, M.D., Ph.D., President of Genomas and Director of Genetics Research at Hartford

Hospital stated: “Personalized healthcare is often referred to as the ‘future of medicine’. In 5 years,

Hartford Hospital and Genomas together have advanced this field to the present for our patients, by

being at the vanguard of the practice of DNA-Guided Medicine. Foremost in my mind is a deep

appreciation to the patients we have served and to the physicians who referred them to us for

improving the safety and efficacy of their drug treatments. At a personal level, I am very honored by

the trust of our collaborators, advisers and investors on the formidable capabilities of the entire

Genomas team and by their sharing our vision of personalized medicine in clinical practice.”

With the motto “Bringing DNA-Guided Medicine to Healthcare Today”, the company will showcase its

various accomplishments to the greater biomedical and business community, including the following:

Translational Medicine Anchored in Hospital Partnerships

  •  Hartford Hospital (cardiovascular), Institute of Living (psychiatry), Hospital of Central Connecticut (diabetes) and University of Puerto Rico Medical Sciences (Hispanic healthcare)
  •  Network of clinical resources, research collaborators, IRB-approved protocols
  •  Numerous medical education workshops and internships

Nationally recognized clinical practice in pharmacogenetics

  •  500 patients referred by physicians, 1,500 pharmacogenetic assays performed
  •  CLIA Certified, State-Licensed Molecular Diagnostics Laboratory of Personalized Health since 2005
  •  CT-wide distribution of clinical services via Clinical Laboratory Partners with payer reimbursement

Validated Science and Proven Technology Platform

  •  $4.3M Research grants from NIH SBIR programs and product development contracts
  •  30 Scientific publications and 5 national symposia
  •  PhysioGenomics Technology for genomic learning from patient care and the observed variability in clinical response to treatments
  •  5,000 Patient clinical database and repository

PhyzioType System™ Product Development Addressing Major Clinical Needs

  •  Novel diagnostic configuration of PhyzioType Systems combines multi-gene DNA marker ensembles, clinically validated algorithms to predict response, physician interface
  •  PIMS PhyzioType™ System for DNA-guided management of Psychotropic-Induced Metabolic
  • Symptoms to be launched Q4 2009
  •  SINM PhyzioType™ System for DNA-guided management of Statin-Induced Neuro-Myopathy to be launched Q2 2010
  • GLIM PhyzioType™ System for DNA-guided management of Glucose and Insulin Modulators in development for diabetes medications

Strong Intellectual Property Estate

  •  2 Patent applications on PhysioGenomics Technology
  •  6 Patent applications on PhyzioType Systems for DNA-Guided Medicine
  •  2 registered trademarks

Seed Round Financing Completed

  •  $5.3M Financing in 3 Series

“In my 6 years at Hartford Hospital I have learned that the Institution thrives on providing the best

patient care while advancing clinical practice. Personalized medicine is part of a long series of

accomplishments first implemented into clinical practice at Hartford Hospital. Our PhyzioType

Systems will follow in that tradition, as patients at this Institution will be the first in the nation to benefit

from this innovative technology in DNA-Guided Medicine. Genomas is deeply indebted to the

Hospital, for pioneering a business model in translational medicine, incubating the company and

becoming its founding partner in 2004,” said Dr. Ruaño.

Elliot Joseph, President and CEO, Hartford Hospital and Hartford Healthcare, commented: “This

anniversary of Genomas is a testament to the company’s contributions not only to the development of

new biomedical technologies but also to the enhancement of patient care. In its 5 years at Hartford

Hospital, Genomas has been instrumental in advancing our institution to become one of the key

national centers of excellence in the clinical practice of personalized medicine.”

ABOUT GENOMAS

Genomas is a biomedical company advancing DNA-Guided Medicine and personalized healthcare. The company develops revolutionary PhyzioType™ Systems for DNA-guided management and prescription of drugs used to treat heart disease, mental illness, and diabetes. PhyzioType Systems are designed to provide physicians with an unprecedented capability to select for each patient the safest and most effective drug treatment to achieve treatment goals and enhance patient compliance. Genomas is located in Hartford, CT on the campus of Hartford Hospital. Please visit www.genomas.com for more information.

ABOUT PHYZIOTYPE SYSTEMS FOR DNA-GUIDED MEDICINE

PhyzioType™ Systems are composed of an ensemble of inherited DNA polymorphisms genotyped by arrays and interpreted by a bioclinical algorithm in order to convey to physicians predicted comparisons of side effect risk among drugs for the individual patient. They are being developed for DNA-Guided Medicine in the prescription of cardiovascular, psychotropic and diabetes drugs and in preventive cardiology. The research leading to the PhyzioType Systems has been published in the renowned journals Annals of Biomedical Engineering, Biomedical Engineering Handbook, Molecular Psychiatry, Muscle & Nerve, Pharmacogenomics and Clinica Chimica Acta.

ABOUT HARTFORD HOSPITAL

Hartford Hospital is an 867-bed regional referral center that provides high-quality care in all clinical disciplines. Among its divisions is The Institute of Living, a 114-bed mental health facility with a national and international reputation of excellence. Jefferson House, a 104-bed long-term care facility, is also a special division of Hartford Hospital. The Hospital major centers of clinical excellence include cardiology, oncology, emergency services and trauma, mental health, women’s health, orthopedics, bloodless surgery and advanced organ transplantation. Hartford Hospital owns and operates the state’s only air ambulance system, LifeStar. Hartford Hospital employs more than 6,600 full-time or part-time employees and a medical staff of more than 970 active staff physicians. Hartford Hospital, founded in 1854, is one of the largest teaching hospitals and tertiary care centers in New England with the region’s busiest surgery practice, and has been training physicians for nearly 130 years. Please visit www.harthosp.org for more information


Share:
  • Print
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • Twitter

Your Comment